Insider Trading June 8, 2026 05:07 PM

Plexus Regional President Michael Running Disposes of $138,804 Worth of Shares

Insider sale occurs as PLXS nears 52-week highs, following strong Q2 earnings beat and upgraded analyst outlooks.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
PLXS

Michael J. Running, Regional President of the Americas at Plexus Corp (NASDAQ: PLXS), executed a sale of 510 shares on June 5, 2026, totaling $138,804 at an average price of $272.165 per share. This transaction reduces his direct holdings to 665 shares. The sale takes place while Plexus stock is trading close to its 52-week high of $292.32, having delivered a 105% return over the past year. The company recently reported robust fiscal Q2 2026 results, beating both earnings and revenue estimates, which has prompted analyst upgrades from Needham and Stifel.

Plexus Regional President Michael Running Disposes of $138,804 Worth of Shares
PLXS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Michael J. Running sold 510 shares of PLXS on June 5, 2026, for $138,804, reducing his direct holdings to 665 shares.
  • Plexus reported strong Q2 2026 financials, with EPS of $2.05 beating the $1.88 forecast and revenue of $1.164 billion exceeding the $1.13 billion estimate.
  • Analyst optimism is growing, with Needham raising its price target to $310 and Stifel maintaining a Buy rating following positive engagements with management.

Michael J. Running, serving as the Regional President for the Americas at Plexus Corp (NASDAQ:PLXS), executed a significant transaction involving the company's equity on June 5, 2026. The insider sold a total of 510 shares of Plexus common stock. The financial value of this divestment was recorded at $138,804. Each share was transacted at a price point of $272.165. Following the completion of this sale, Mr. Running's direct ownership stake in Plexus common stock stands at 665 shares.

This insider activity emerges against a backdrop of strong market performance for Plexus. The company's shares are currently trading in close proximity to their 52-week high, which is recorded at $292.32. Over the trailing twelve-month period, the stock has generated a total return of 105%. Market analysis from InvestingPro suggests that the current valuation of the stock may be elevated. The analysis indicates that Plexus appears overvalued at these levels. Subscribers to the service have access to 15 additional ProTips related to the stock. Plexus is also included in InvestingPro's list of Most Overvalued stocks.

On the fundamental front, Plexus Corp delivered financial results for fiscal Q2 2026 that exceeded market expectations. The company reported earnings per share (EPS) of $2.05. This performance surpassed the consensus forecast of $1.88. Revenue for the quarter was reported at $1.164 billion. This figure also beat the projected revenue of $1.13 billion. These results underscore a period of solid operational performance for the company.

Analyst sentiment regarding Plexus has also turned more positive. Needham recently raised its price target for Plexus shares from $285 to $310. The firm maintained a Buy rating on the stock. This adjustment followed meetings with company management, during which Needham expressed heightened confidence in Plexus's growth trajectory and margin expansion opportunities. Similarly, Stifel reiterated its Buy rating on Plexus. Stifel maintained a price target of $280 following a site visit to the company's facilities in Wisconsin. These analyst actions suggest a favorable outlook from the investment community regarding the company's future prospects.

Risks

  • InvestingPro analysis indicates that Plexus stock appears overvalued at current levels, suggesting potential downside risk if valuation multiples compress.
  • The stock's 105% return over the past year and proximity to its 52-week high of $292.32 may indicate a period of heightened volatility or correction risk for investors.
  • Insider sales by executive management, such as the recent transaction by Regional President Michael Running, may signal a lack of immediate confidence in further near-term upside at current prices.

More from Insider Trading

HRT Financial Liquidates Remaining Aditxt Holdings Following Sharp Stock Decline Jun 8, 2026 Glenbrook Capital Management Acquires Additional SenesTech Shares Amidst Strategic Shifts Jun 8, 2026 USANA Health Sciences Chief People Officer Liquidates Full Shareholding Jun 8, 2026 Werewolf Therapeutics Director Luke Evnin Offloads Shares via Rule 10b5-1 Plan Jun 8, 2026 BlackLine Director Mika Yamamoto Divests $85,000 in Stock Amid Analyst Revisions Jun 8, 2026